Familial and developmental abnormalities of frontal lobe function and neurochemistry in schizophrenia

Journal of Psychopharmacology

Volumn 11, Issue 2, 1997, Pages 133-142

  Deakin, J F W ^a   Simpson, M D C ^a   Slater, P ^a   Hellewell, J S E ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Frontal lobe; Genetics; Glutamate; Schizophrenia; Serotonin; Temporal lobe

Indexed keywords

4 AMINOBUTYRIC ACID; BIOCHEMICAL MARKER; CYCLOSERINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GLYCINE; MILACEMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT;

AUTOPSY; BRAIN CORTEX; BRAIN DEVELOPMENT; BRAIN DYSFUNCTION; BRAIN FUNCTION; BRAIN METABOLISM; CLINICAL TRIAL; DEVELOPMENTAL DISORDER; FAMILY STUDY; FRONTAL LOBE; GABAERGIC TRANSMISSION; GENETIC PREDISPOSITION; HIPPOCAMPUS; HUMAN; NERVE PROJECTION; NEUROCHEMISTRY; NEUROPATHOLOGY; NEUROPSYCHOLOGY; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; REVIEW; SCHIZOPHRENIA; SENSORY NERVE; TEMPORAL CORTEX;

ANTIPSYCHOTIC AGENTS; BRAIN MAPPING; FRONTAL LOBE; GLUTAMIC ACID; HUMANS; NEURAL PATHWAYS; NEUROTRANSMITTER AGENTS; PREFRONTAL CORTEX; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TEMPORAL LOBE;

EID: 0030905711     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988119701100206     Document Type: Review

References (94)

1. Akbarian S, Kim J J, Potkin S G, Hagman J O, Tafazzoli A, Bunney W E Jr, Jones E G (1995) Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiat 52: 258-266
2. Akbarian S, Sucher N J, Bradley D, Tafazzoli A, Trinh D, Hetrick W P, Potkin S G, Sandman C A, Bunney Jr WE, Jones E G (1996) Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 16: 19-30
3. Andreasen N C, Flashman L, Flaum M, Arndt S, Swayze VW 2nd, O'Leary D S, Ehrhardt J C, Yuh W T C (1994) Regional brain abnormalities in schizophrenia measured with magnetic resonance imaging. JAMA 272: 1763-1769
4. Arora R C, Meltzer H Y (1991) Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients. J Neural Transm 85: 19-29
5. Bashir Z I, Tam B, Collingridge G L (1990) Activation of the glycine site in the NMDA receptor is necessary for the induction of LTP. Neurosci Letts 108: 261-266
6. Benes F M (1989) Myelination of cortical-hippocampal relays during late adolescence. Schizophr Bull 15: 585-593
7. Benes F M, Davidson J, Bird E D (1986) Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics. Arch Gen Psychiat 43: 31-35
8. Benes F M, McSparren J, Bird E D, SanGiovanni J P, Vincent S L (1991) Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiat 48: 996-1001
9. Benes F M, Sorensen I, Vincent S L, Bird E D, Sathi M (1992a) Increased density of glutamate-immunoreactive vertical processes in superficial laminae in cingulate cortex of schizophrenic brain. Cerebral Cortex 2: 503-512
10. Benes F M, Vincent S L, Alsterberg G, Bird E D, SanGiovanni J P (1992b) Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci 12: 924-929
11. Benes F M, Turtle M, Khan Y, Farol P (1994) Myelination of a key relay zone in the hippocampal formation occurs in the human brain during childhood, adolescence, and adulthood. Arch Gen Psychiat 51: 477-484
12. Bennett J P Jr, Enna S J, Bylund D B, Gillin J C, Wyatt R J, Snyder S H (1979) Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiat 36: 927-934
13. Bristow L J, Hutson P H, Thorn L, Tricklebank M D (1993) The glycine/NMDA receptor antagonist, R-(+)-HA-966, blocks activation of the mesolimbic dopaminergic system induced by phencyclidine and dizocilpine (MK-801) in rodents. Br J Pharmac 108: 1156-1163
14. Bristow L J, Thorn L, Tricklebank M D, Hutson P H (1994) Competitive NMDA receptor antagonists attenuate the behavioural and neurochemical effects of amphetamine in mice. Eur J Pharmac 264: 353-359
15. Brody D, Adler L A, Kim T, Angrist B, Rotrosen J (1990) Effects of buspirone in seven schizophrenic patients. J Clin Psychopharmac 10: 68-69
16. Burnet P W J, Eastwood S L, Lacey K, Harrison P J (1995) The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain. Brain Res 676 (1): 157-168
17. Burnet P W J, Eastwood S L, Harrison P J (1996) 5HT1A and 5HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 15: 442-455
18. Cascella N G, Macciardi F, Cavallini C, Smeraldi E (1994) D-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. J Neur Transm 95: 105-111
19. Chua S E, McKenna P J (1995) Schizophrenia - a brain disease - a critical review of structural and functional cerebral abnormality in the disorder. Br J Psychiat 166: 563-582
20. Costa J, Khaled E, Sramek J, Bunney W Jr, Potkin S G (1990) An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics. J Clin Psychopharmac 10: 71-72
21. Crino P B, Vogt B A, Volicer L, Wiley R G (1990) Cellular localisation of serotonin 1A, 1B and uptake sites in cingulate cortex of the rat. J Pharmac Exp Ther 252: 651-656
22. Deakin J F W, Slater P, Simpson M D C, Gilchrist A C, Skan W J, Royston M C, Reynolds G P, Cross A J (1989) Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem 52: 1781-1786
23. Dijk S N, Francis P T, Stratmann G C, Bowen D M (1995) NMDA-induced glutamate and aspartate release from rat cortical pyramidal neurones: evidence for modulation by a 5-HT1A antagonist. Br J Pharmac 115: 1169-1174
24. Domino E F (1980) History and pharmacology of PCP and PCP-related analogs. J Psyched Drugs 12: 223-227
25. Eccleston D, Fairbairn A F, Hassanyeh F (1985) The effect of propranolol and thioridazine on positive and negative symptoms of schizophrenia. Br J Psychiat 147: 623-630
26. Fonnum F (1984) Glutamate a neurotransmitter in mammalian brain. J Neurochem 42: 1-11
27. Francis P T, Pangalos M N, Pearson R C A, Middlemiss D N, Stratmann G C, Bowen D M (1992) 5-Hydroxytryptamine-1A but not 5-hydroxytryptamine-2 receptors are enriched on neocortical pyramidal neurones destroyed by intrastriatal volkensin. J Pharmac Exp Ther 261: 1273-1281
28. Goff D C, Midha K K, Brotman A W, McCormick S, Waites M, Amico E T (1991) An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmac 11: 193-197
29. Goff D C, Tsai G, Manoach D S, Coyle J T (1995) Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiat 152: 1213-1215
30. Gould E, McEwen B S (1993) Neuronal birth and death. Curr Opin Neurobiol 3: 676-682
31. 3H]muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sci 40: 259-266
32. Harvey I, Persaud R, Ron M A, Baker G, Murray R M (1994) Volumetric MRI measurements in bipolars compared with schizophrenics and healthy controls. Psychol Med 24: 689-699
33. Hashimoto T, Nishino N, Nakai H, Tanaka C (1991) Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci 48: 355-363
34. Hellewell J S E, Deakin J F W (1994) Impaired frontal lobe function in schizophrenia is familial. Schizophr Res 11: 149
35. Huettner J E (1989) Indole-2-carboxylic acid: a competitive antagonist of potentiation by glycine at the NMDA receptor. Science 243: 1611-1613
36. Humphries C R, Virgo L, Mortimer A, Barnes T, Hirsch S, de Belleroche J (1995) The expression of the N-methyl-D-aspartate receptor subunit NR-1 is decreased in schizophrenia. Schizophr Res 15: 60
37. Hutson P H, Bristow L J, Thorn L, Tricklebank M D (1991) R-(+)-HA-966, a glycine/NMDA receptor antagonist, selectively blocks the activation of the mesolimbic dopamine system by amphetamine. Br J Pharmac 103: 2037-2044
38. Ishimaru M, Kurumaji A, Toru M (1992) NMDA-associated glycine binding site increases in schizophrenic brains. Biol Psychiat 32: 379-381
39. Ishimaru M, Kurumaji A, Toru M (1994) Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. Biol Psychiat 35: 84-95
40. Javitt D C (1987) Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. J Clin Psychiat 9: 12-35
41. Javitt D C, Zylberman I, Zukin S R, Heresco-Levy U, Lindenmayer J P (1994) Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiat 151: 1234-1236
42. Joyce J N, Shane A, Lexow N, Winokur A, Casanova M F, Kleinman J E (1993) Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 8: 315-336
43. Kemp J A, Foster A C, Leeson P D, Priestley T, Tridgett R, Iversen L L, Woodruff G N (1988) 7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex. Proc Nat Acad Sci USA 85: 6547-6550
44. King D J, Turkson N A, Liddle J, Kinney C D (1980) Some clinical and metabolic aspects of propranolol in chronic schizophrenia. Br J Psychiat 137: 458-468
45. Kiuchi Y, Kobayashi T, Takeuchi J, Shimizu H, Ogata H, Toru M (1989) Benzodiazepine receptors increase in post-mortem brain of chronic schizophrenics. Eur Arch Psychiat Neurol Sci 239: 71-78
46. Kleckner N W, Dingledine R (1988) Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science 241: 835-837
47. 3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 77: 231-236
48. Korpi E R, Kleinman J E, Goodman S I, Wyatt R J (1987) Neurotransmitter amino acids in post-mortem brains of chronic schizophrenic patients. Psychiat Res 22: 291-301
49. Kotrla K J, Weinberger D R (1995) Brain imaging in schizophrenia. Ann Rev Med 46: 113-122
50. 3H]amino-3-hydroxy-5-methylisoxazole-4-propionic acid binding to human cerebral cortical membranes: minimal changes in postmortem brains of chronic schizophrenics. J Neurochem 59: 829-837
51. Kutay F Z, Pogun S, Hariri N I, Peker G, Erlacin S (1989) Free amino acid level determinations in normal and schizophrenic brain. Prog Neuropsychopharmac Biol Psychiat 13: 119-126
52. Lane A, Kinsella A, Waddington JL, Larkin C, O'Callaghan E (1996) Quantitative evidence of developmental instability in schizophrenia as measured by fluctuating asymmetry. Schizophr Res 18 (2,3): 169-170
53. Leiderman E, Zylberman I, Zukin S R, Cooper T B, Javitt D C (1996) Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: An open-label trial. Biol Psychiat 39: 213-215
54. Liddle P F, Spence S A, Sharma T, Hellewell J S E, McGuire P, Deakin J F W, Murray R M, Friston K J, Frith C D (1995) A PET study of obligate carriers of the predisposition to schizophrenia. Schizophr Res 15: 90
55. 3H]AMPA binding in frontal cortex in schizophrenia. Schizophr Res 11: 121
56. Maj J, Rogoz Z, Skuza G, KoLodziejczyk K (1994) Some central effects of kynurenic acid, 7-chlorokynurenic acid and 5,7-dichloro-kynurenic acid, glycine site antagonists. Pol J Pharmac 46: 115-124
57. Manchanda R, Hirsch S R (1986) Does propranolol have an antipsychotic effect? A placebo-controlled study in acute schizophrenia. Br J Psychiat 148: 701-707
58. Markowitz J S, Wells B G, Carson W H (1995) Interactions between antipsychotic and antihypertensive drugs. Annls Pharmacother 29: 603-609
59. McCormick D A, Williamson A (1989) Convergence and divergence of neurotransmitter action in human cerebral cortex. Proc Nat Acad Sci USA 86: 8098-8102
60. Myers D H, Campbell P L, Cocks N M, Flowerdew J A, Muir A (1981) A trial of propranolol in chronic schizophrenia. Br J Psychiat 139: 118-121
61. Nakai T, Hashimoto T, Kitamura N, Nishino N, Shirakawa O, Hanada S, Mita T, Tanaka C (1988) Alterations of neurotransmitter receptors in schizophrenic patients. Psychopharmacology 96 (Suppl): 187
62. 3H]kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci Letts 40: 245-250
63. Pantelis C, Barnes T R E (1993) Acute exacerbation of psychosis with buspirone? J Psychopharmac 7: 295-300
64. Peet M, Bethell M S, Coates A, Khamnee A K, Hall P, Cooper S J, King D J, Yates R A (1981) Propranolol in schizophrenia. I. Comparison of propranolol, chlorpromazine and placebo. Br J Psychiat 135: 105-111
65. Perry T L (1982) Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci Letts 28: 81-85
66. Pugh C R, Steinert J, Priest R G (1983) Propranolol in schizophrenia: a double blind, placebo controlled trial of propranolol as an adjunct to neuroleptic medication. Br J Psychiat 143: 151-155
67. Reynolds G P (1991) Amino acid transmitters and dopamine function in the brain in schizophrenia. In Racagni G, Brunello N, Fokuda T (eds), Biological psychiatry. Excerpta Medica, Amsterdam, pp. 491-494
68. Reynolds G P, Cutts A J, Mason S L (1993) Temporal, but not frontal, cortical glutamatergic deficits in schizophrenia. Schizophr Res 9: 150
69. Reynolds I J, Miller R J (1990) Allosteric modulation of N-methyl-D-aspartate receptors. Adv Pharmac 21: 101-126
70. Rosse R B, Theut S K, Banay-Schwartz M, Leighton M, Scarcella E, Cohen C G, Deutsch S I (1989) Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. Clin Neuropharmac 12: 416-424
71. Rosse R B, Schwartz B L, Leighton M P, Davis R E, Deutsch S I (1990) An open-label trial of milacemide in schizophrenia: an NMDA intervention strategy. Clin Neuropharmac 13: 348-545
72. Rosse R B, Schwartz B L, Davis R E, Deutsch S I (1991) An NMDA intervention strategy in schizophrenia with 'low-dose' milacemide. Clin Neuropharmac 14: 268-272
73. Selemon L D, Rajkowska G, Goldman-Rakic P S (1995) Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiat 52: 805-818
74. Sethi B B, Dube S (1983) Propranolol in schizophrenia. Prog Neuropsychopharmac Biol Psychiat 7: 89-99
75. Simpson M D C, Slater P, Royston M C, Deakin J F W (1991) Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication. Schizophr Res 6: 41-48
76. Simpson M D C, Royston M C, Slater P, Deakin J F W (1992) Neurochemical abnormalities of the cerebral cortex in schizophrenia. Schizophr Res 6: 133-134
77. Simpson M D C, Slater P, Deakin J F W (1993) Asymmetric changes in the neurochemical morphology of ventro-medial frontal cortex in schizophrenia. Schizophr Res 9: 228
78. 3H]8-OH-DPAT reveals increases in 5-HT1A receptors in ventral prefrontal cortex in schizophrenia. Biol Psychiat 39(2): 919-928
79. Singh L, Donald AE, Foster AC, Hutson PH, Iversen LL, Iversen S D, Kemp J A, Leeson P D, Marshall G R, Oles R J (1990) Enantiomers of HA-966 (3-amino-1-hydroxypyrrolid-2-one) exhibit distinct central nervous system effects: (+)-HA-966 is a selective glycine/N-methyl-D-aspartate receptor antagonist, but (-)-HA-966 is a potent gamma-butyrolactone-like sedative. Proc Nat Acad Sci USA 87: 347-351
80. Slater P, McConnell S, Dsouza S W, Barson A J, Simpson M D C, Gilchrist A C (1992) Age-related changes in binding to excitatory amino acid uptake site in temporal cortex of human brain. Dev Brain Res 65(2): 157-160
81. Sovner R, Parnell-Sovner N (1989) Use of buspirone in the treatment of schizophrenia. J Clin Psychopharmac 9: 61-62
82. Spence S, Liddle P, Herold S, Fletcher P, Friston K, Frith C (1995) Medial frontal lobe overactivity in reality distortion syndrome during word generation: a PET study. Schizophr Res 15 (1,2): 99
83. Steit P (1984) Glutamate and aspartate as transmitter candidates for systems of the cerebral cortex. In Jones EG, Peters A (eds), Cerebral cortex. Plenum Press, New York, pp. 119-143
84. Suga I, Kobayashi T, Ogata H, Toru M (1990) Increased 3H-MK801 binding sites in post-mortem brains of chronic schizophrenic patients. Proceedings of the 17th Collegium Internationale Neuro-Psychopharmacologium S2: 28
85. Waziri R (1988) Glycine therapy of schizophrenia. Biol Psychiat 23: 210-211
86. Weissman A D, Casanova M F, Kleinman J E, London E D, De Souza E B (1991) Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol Psychiat 29: 41-54
87. Whitaker P M, Crow T J, Ferrier I N (1981) Tritiated LSD binding in frontal cortex in schizophrenia. Arch Gen Psychiat 38: 278-280
88. Wood P L (1995) The co-agonist concept: Is the NMDA-associated glycine receptor saturated in vivo? Life Sci 57: 301-310
89. Wu G-Y, Malinow R, Cline H T (1996) Maturation of a central glutamatergic synapse. Science 274: 972-976.
90. Yang Q, Moroji T, Takamatsu Y, Hagino Y, Okuwa M (1991) The effects of intraperitoneally administered phencyclidine on the central nervous system: behavioral and neurochemical studies. Neuropeptides 19: 77-90
91. Yorkston N J, Zaki S A, Themen J F, Havard C W (1976) Safeguards in the treatment of schizophrenia with propranolol. Postgrad Med J 52 (Suppl.4): 175-180
92. Yorkston N J, Zaki S A, Pitcher D R, Gruzelier J H, Hollander D, Sergeant H G (1977) Propranolol as an adjunct to the treatment of schizophrenia. Lancet 2: 575-578
93. Yorkston N J, Zaki S A, Weller M P, Gruzelier J H, Hirsch S R (1981) DL-propranolol and chlorpromazine following admission for schizophrenia. A controlled comparison. Acta Psychiat Scand 63: 13-27
94. Zipursky R B, Marsh L, Lim K O, DeMent S, Shear P K, Sullivan E V, Murphy G M, Csernansky J G, Pfefferbaum A (1994) Volumetric MRI assessment of temporal lobe structures in schizophrenia. Biol Psychiat 35: 501-516